エピソード

  • Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh

    Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh
    2026/09/01
    For more than a decade, THP—established by the landmark CLEOPATRA trial— defined the first-line standard for HER2-positive metastatic breast cancer. Now, DESTINY-Breast09 is changing the conversation.In this CHM Conversation, Dr. Sonya Reid and Dr. Shruti Singh discuss the evolving first-line treatment landscape and how trastuzumab deruxtecan (T-DXd) plus pertuzumab is reshaping clinical decision-making for patients with HER2-positive metastatic breast cancer.They explore which patients may benefit most from a T-DXd-based approach, how prior T-DXd exposure in early-stage disease could influence treatment at metastatic recurrence, and where THP may still have a role. The conversation also examines practical considerations around toxicity management, maintenance strategies in HER2+ disease, sequencing, and individualized treatment selection.Topics discussed:How CLEOPATRA and THP established the first-line standardDESTINY-Breast09 and T-DXd plus pertuzumabTreatment considerations for high-risk and HR+/HER2+ diseaseBrain metastases and high visceral disease burdenHow prior neoadjuvant or adjuvant T-DXd may influence treatmentManaging nausea, fatigue, and ILD with T-DXdDose modifications and maintaining quality of life with T-DXdPATINA and HER2CLIMB-05 maintenance approachesTreatment sequencing after first-line T-DXd plus pertuzumab▶️ Watch the full conversation and subscribe to Community Health Media for more expert perspectives on the latest research and evolving approaches in cancer care.#CHMConversations #SonyaReid #ShrutiSingh #HER2Positive #MetastaticBreastCancer #DESTINYBreast09 #TDXd #TrastuzumabDeruxtecan #BreastCancer #BreastOncology #MedicalOncology #CommunityHealthMedia– Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast... • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o– Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media
    続きを読む 一部表示
    29 分
  • This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran

    This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran
    2026/08/13

    Are antibody-drug conjugates becoming the new first-line standard for metastatic triple-negative breast cancer?


    At This Moment in Medicine, hosted by Community Health Media, Dr. Senthil Damodaran reviews the latest data moving ADCs earlier in the treatment landscape for metastatic TNBC.


    The presentation focuses on TROPION-Breast02, ASCENT-03, and ASCENT-04, comparing datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan with chemotherapy, with or without pembrolizumab depending on PD-L1 status. Dr. Damodaran also examines efficacy, toxicity, sequencing, and the practical tradeoffs that may influence which ADC clinicians choose.


    Topics discussed:

    • Historical first-line treatment of metastatic TNBC
    • TROPION-Breast02 and Dato-DXd
    • ASCENT-03 and sacituzumab govitecan in PD-L1-negative disease
    • ASCENT-04 and sacituzumab govitecan plus pembrolizumab
    • Progression-free survival, overall survival, and response rates
    • Toxicity differences between Dato-DXd and sacituzumab govitecan
    • Stomatitis, ocular toxicity, neutropenia, and supportive care
    • Whether TROP-2 expression should guide treatment
    • BRCA mutations and where PARP inhibitors may still fit
    • CNS activity and intracranial disease
    • Choosing between Dato-DXd and sacituzumab govitecan
    • ADCs sequencing


    The presentation concludes with a practical discussion on one of the biggest questions in TNBC today: If both ADCs are effective, how should clinicians choose between them?


    ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert discussions on the latest advances shaping cancer care.

    🎧 Subscribe for the latest insights from leading cancer specialists.


    #ThisMomentInMedicine #SenthilDamodaran #TripleNegativeBreastCancer #TNBC #ADC #DatoDXd #SacituzumabGovitecan #TROPIONBreast02 #ASCENT03 #ASCENT04 #MedicalOncology #CommunityHealthMedia

    –


    Thanks for watching!


    Our podcasts are also available on:

    • Spotify - https://spotf.fi/chm-podcast

    • Amazon Music - https://amazn.so/chm-podcast

    • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

    • Castbox - https://castbox.fm/vh/6735434

    • Goodpods - https://goodpods.com/profile/chm-111066

    • iHeartRadio - https://iheart.com/podcast/291542082

    • Pocket Casts - https://pca.st/3ncdh11o


    –


    Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.


    We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.


    We specialize in:

    • Peer to peer interviews, panels & round-tables

    • Curated live events & conferences

    • Professional in-depth content & research updates

    • Interactive learning modules & webinars

    • Live & on-demand webcasts & podcasts


    Learn more about us here - https://communityhealth.media
    続きを読む 一部表示
    25 分
  • This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

    This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi
    2026/08/13

    How should we approach first-line treatment as the HER2-positive metastatic breast cancer landscape rapidly evolves?


    At This Moment in Medicine, hosted by Community Health Media, Dr. Mothaffar Rimawi examines how new data are reshaping a treatment landscape long defined by the CLEOPATRA regimen.


    From DESTINY-Breast09 to PATINA and HER2CLIMB-05, Dr. Rimawi explores emerging strategies for deeper HER2 and ER pathway inhibition, the role of T-DXd, and how clinicians might individualize treatment based on disease biology, burden, toxicity, and patient preference.


    Topics discussed:

    • The evolution of first-line HER2-positive metastatic breast cancer treatment
    • CLEOPATRA and the foundation of modern HER2-directed therapy
    • PATINA and the addition of palbociclib in HR+/HER2+ disease
    • DESTINY-Breast09 and T-DXd plus pertuzumab
    • Depth and duration of response with T-DXd
    • HER2CLIMB-05 and tucatinib maintenance
    • ILD, transaminitis, and other treatment-related toxicities
    • Patient-reported outcomes and quality of life
    • Selecting treatment based on ER status, CNS disease, disease burden, and molecular profile
    • T-DXd duration and the possibility of induction-maintenance strategies
    • How PATINA and HER2CLIMB-05 could inform maintenance therapy


    The presentation concludes with a panel discussion addressing a critical question for the field: With several highly effective strategies now available, how do we choose the right first-line approach for the right patient?


    ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert conversations on the latest advances shaping cancer care.

    🎧 Subscribe for the latest insights from leading cancer specialists.


    #ThisMomentInMedicine #MothaffarRimawi #HER2Positive #MetastaticBreastCancer #DESTINYBreast09 #TDXd #PATINA #HER2CLIMB05 #BreastOncology #MedicalOncology #CommunityHealthMedia

    –


    Thanks for watching!


    Our podcasts are also available on:

    • Spotify - https://spotf.fi/chm-podcast

    • Amazon Music - https://amazn.so/chm-podcast

    • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

    • Castbox - https://castbox.fm/vh/6735434

    • Goodpods - https://goodpods.com/profile/chm-111066

    • iHeartRadio - https://iheart.com/podcast/291542082

    • Pocket Casts - https://pca.st/3ncdh11o


    –


    Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.


    We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.


    We specialize in:

    • Peer to peer interviews, panels & round-tables

    • Curated live events & conferences

    • Professional in-depth content & research updates

    • Interactive learning modules & webinars

    • Live & on-demand webcasts & podcasts


    Learn more about us here - https://communityhealth.media
    続きを読む 一部表示
    21 分
  • This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo

    This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo
    2026/08/13

    Where should T-DXd fit in the treatment of high-risk, early-stage HER2-positive breast cancer?


    At This Moment in Medicine, hosted by Community Health Media, Dr. Michelina Cairo reviews the latest data from DESTINY-Breast11 and DESTINY-Breast05, examining how trastuzumab deruxtecan (T-DXd) could reshape treatment in both the neoadjuvant and adjuvant settings.


    From pathologic complete response and invasive disease-free survival to ILD risk and treatment sequencing, the presentation explores how clinicians might balance efficacy, toxicity, and individual recurrence risk as T-DXd moves into earlier-stage disease.


    Topics discussed:

    • Current treatment for high-risk HER2-positive early breast cancer
    • DESTINY-Breast11 and neoadjuvant T-DXd followed by THP
    • Pathologic complete response and residual cancer burden
    • DESTINY-Breast05 and T-DXd versus T-DM1
    • Invasive disease-free survival and emerging CNS outcomes
    • ILD, nausea, cardiac safety, and treatment duration
    • Neoadjuvant versus adjuvant use of T-DXd
    • Whether THP alone may be sufficient for selected patients
    • The potential role of ctDNA
    • Where T-DM1 may still fit for residual disease
    • Individualizing treatment according to recurrence risk


    The presentation concludes with a panel discussion exploring one of the biggest unanswered questions: How much T-DXd is enough—and when should it be used?


    ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert conversations on the latest advances shaping cancer care.

    🎧 Subscribe for the latest insights from leading cancer specialists.


    #ThisMomentInMedicine #MichelinaCairo #BreastCancer #HER2Positive #TDXd #TrastuzumabDeruxtecan #DESTINYBreast11 #DESTINYBreast05 #BreastOncology #MedicalOncology #CommunityHealthMedia

    –


    Thanks for watching!


    Our podcasts are also available on:

    • Spotify - https://spotf.fi/chm-podcast

    • Amazon Music - https://amazn.so/chm-podcast

    • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

    • Castbox - https://castbox.fm/vh/6735434

    • Goodpods - https://goodpods.com/profile/chm-111066

    • iHeartRadio - https://iheart.com/podcast/291542082

    • Pocket Casts - https://pca.st/3ncdh11o


    –


    Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.


    We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.


    We specialize in:

    • Peer to peer interviews, panels & round-tables

    • Curated live events & conferences

    • Professional in-depth content & research updates

    • Interactive learning modules & webinars

    • Live & on-demand webcasts & podcasts


    Learn more about us here - https://communityhealth.media
    続きを読む 一部表示
    25 分
  • This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri

    This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri
    2026/08/13

    How is adjuvant treatment for ER-positive, HER2-negative breast cancer changing?


    At This Moment in Medicine, Dr. Akshjot Puri examines key data from OPTIMA, lidERA, NATALEE, and monarchE—and what these trials could mean for chemotherapy de-escalation, endocrine therapy, ovarian suppression, and CDK4/6 inhibitor use.


    From using Prosigna to identify patients who may be able to avoid chemotherapy to the emerging role of oral SERDs, the presentation highlights how treatment is becoming increasingly individualized based on risk, biology, and patient needs.


    Topics discussed:

    • OPTIMA and Prosigna-guided chemotherapy de-escalation
    • Chemotherapy benefit in premenopausal and postmenopausal patients
    • The role of ovarian function suppression
    • Oncotype DX, MammaPrint, and Prosigna
    • lidERA and giredestrant in the adjuvant setting
    • NATALEE vs. monarchE
    • Ribociclib and abemaciclib in early-stage disease
    • ctDNA and emerging biomarkers for treatment selection
    • Individualizing therapy for intermediate- and high-risk patients


    ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert discussions on the latest advances shaping cancer care.

    🎧 Subscribe for the latest insights from leading cancer specialists.


    #ThisMomentInMedicine #AkshjotPuri #BreastCancer #ERPositive #HER2Negative #OPTIMA #Prosigna #Giredestrant #NATALEE #MonarchE #BreastOncology #CommunityHealthMedia

    –


    Thanks for watching!


    Our podcasts are also available on:

    • Spotify - https://spotf.fi/chm-podcast

    • Amazon Music - https://amazn.so/chm-podcast

    • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

    • Castbox - https://castbox.fm/vh/6735434

    • Goodpods - https://goodpods.com/profile/chm-111066

    • iHeartRadio - https://iheart.com/podcast/291542082

    • Pocket Casts - https://pca.st/3ncdh11o


    –


    Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.


    We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.


    We specialize in:

    • Peer to peer interviews, panels & round-tables

    • Curated live events & conferences

    • Professional in-depth content & research updates

    • Interactive learning modules & webinars

    • Live & on-demand webcasts & podcasts


    Learn more about us here - https://communityhealth.media
    続きを読む 一部表示
    28 分
  • Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC

    Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC
    2026/07/21
    A new era in HER2-positive metastatic breast cancer is here.Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09 trial and discuss how trastuzumab deruxtecan (T-DXd) plus pertuzumab is redefining first-line treatment.The conversation explores:Why DB09 may replace the CLEOPATRA standardThe significance of 40+ month median PFSComplete response rates and treatment durabilityManaging ILD, fatigue, nausea, and alopeciaMaintenance therapy strategiesPATINA and HER2CLIMB-05 insightsSequencing after T-DXd progressionWhy “saving your best drug for later” may no longer applyThis is a must-watch discussion on the evolving frontline landscape in HER2+ metastatic breast cancer.–Thanks for watching!Our podcasts are also available on:Spotify - https://spotf.fi/chm-podcastAmazon Music - https://amazn.so/chm-podcastApple Podcast - https://podcasts.apple.com/us/podcast...Castbox - https://castbox.fm/vh/6735434Goodpods - https://goodpods.com/profile/chm-111066iHeartRadio - https://iheart.com/podcast/291542082Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media
    続きを読む 一部表示
    55 分
  • Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC

    Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC
    2026/07/07
    Can we improve outcomes by changing treatment before radiographic progression occurs?In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones explore how the SERENA-6 trial is reshaping the management of HR-positive, HER2-negative metastatic breast cancer through ctDNA-guided treatment decisions and earlier intervention for emerging ESR1 mutations.Topics discussed include:The clinical impact of the SERENA-6 trialUsing ctDNA to detect ESR1 mutations before disease progressionWhen and why to switch endocrine therapyCamizestrant and molecularly guided treatment strategiesIntegrating biomarker monitoring into routine clinical practicePatient communication, monitoring, and quality-of-life considerationsPractical challenges and implementation in the community settingFeaturing expert insights from Dr. Anne O'Dea and Dr. Mabel Mardones on one of the most important advances in precision oncology for HR-positive metastatic breast cancer.Watch the full conversation and subscribe for more expert discussions on the latest clinical evidence shaping cancer care.–Thanks for watching!Our podcasts are also available on:Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠
    続きを読む 一部表示
    32 分
  • Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09

    Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09
    2026/06/26
    HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and into metastatic disease?In this in-depth discussion, Dr. Rena Callahan and Dr. Aditya Bardia explore how these landmark studies are changing treatment decisions today across neoadjuvant, adjuvant, and metastatic settings—including the management of residual disease and the optimization of first-line metastatic care.Key topics discussed:How DESTINY-Breast11 is changing neoadjuvant treatment strategiesDESTINY-Breast05 and the role of T-DXd for residual diseaseWhich patients should receive T-DXd versus T-DM1Managing ILD risk and monitoring requirementsTreatment decisions for patients who do not achieve pCRRechallenging T-DXd after recurrenceFirst-line metastatic HER2-positive breast cancer after DESTINY-Breast09Deep responses, complete responses, and long-term outcomesT-DXd versus THP in clinical practicePATINA, HER2CLIMB-05, and evolving maintenance strategiesCNS metastases and the role of HER2-targeted ADCsTreatment holidays, ctDNA monitoring, and personalized careAs T-DXd moves into earlier lines of therapy, oncologists are facing new questions around sequencing, toxicity management, and optimizing long-term outcomes. This conversation provides practical insights for both academic and community clinicians navigating this rapidly changing landscape.Subscribe for more expert oncology discussions, breast cancer updates, and clinical trial insights from Community Health Media.–Thanks for watching!Our podcasts are also available on:Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠
    続きを読む 一部表示
    33 分